The transcription factor NF-B is an important component in the human immune response and is now known to be dysregulated in many major human diseases. For example, chronic activation of NF-B is associated with arthritis, colitis, dermatitis, asthma and other inflammatory diseases. Additionally, NF-B activation is strongly correlated with cancer development and with the resistance of cancer to a variety of therapeutic interventions. While the inhibition of NF-B is likely to be highly therapeutic, historically there have been no specific NF-B inhibitors available for the treatment for disease.

The goal of Theralogics is to develop rational strategies for the safe and predictable inhibition of the NF-B signaling pathway in a wide range of human diseases. In this regard, Theralogics investigators have developed and patented a novel mechanism that suppresses NF-B activation associated with chronic inflammation while protecting NF-B activity in other vital pathways. Additionally, Theralogics' investigators have identified previously untreatable diseases (e.g., Muscular Dystrophy) as involving NF-B activation, thus raising the potential for new therapeutic options for these patients.